Suchergebnisse - "Srinivasan, Shankar"

PubPharm (68)

1

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer : Analyses of the Randomized Phase 3 ARASENS Study

enthalten in: European urology | 2024

von Saad, F. | Hussain, M. | Tombal, B. | +15

2

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial

enthalten in: The oncologist | 2024

von Shore, N. | Hussain, M. | Saad, F. | +10

3

Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Fizazi, K. | Shore, N. | Smith, M. | +8

4

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Hussain, M. | Tombal, B. | Saad, F. | +16

CommentIn: J Clin Oncol. 2023 Jul 10;41(20):3576-3579. - PMID 36947730

5

Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer : ARAMIS subgroup analysis

enthalten in: Future oncology (London, England) | 2023

von Carles, J. | Medina-Lopez, R. | Puente, J. | +11

6

Impact of darolutamide on local symptoms : pre-planned and post hoc analyses of the ARAMIS trial

enthalten in: BJU international | 2023

von Shore, N. | Stenzl, A. | Pieczonka, C. | +8

7

Digital health prognostic analyzer for multiple myeloma mortality predictions

enthalten in: Europäisches Patentamt | 2023

von SRINIVASAN SHANKAR SWAMIMALAI | ELION-MBOUSSA ALBERT

8

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time : Planned Subgroup Analysis of the Phase 3 ARAMIS Trial

enthalten in: European urology | 2023

von Bögemann, M. | Shore, N. | Smith, M. | +16

ErratumIn: Eur Urol. 2023 Feb;83(2):e60. - PMID 36526492

9

Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time : Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022

enthalten in: European urology | 2023

von Bögemann, M. | Shore, N. | Smith, M. | +16

ErratumFor: Eur Urol. 2022 Sep 8;:. - PMID 36089529

10

Machine Learning to Predict 10-year Cardiovascular Mortality from the Electrocardiogram: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III)

enthalten in: bioRxiv.org | 2023

von Kim, C. | Al-Kindi, S. | Tarabichi, Y. | +3

1
2
3
4
5
6
7
Nächster »
[7]